Answers are grounded in this paper and cite their sources.
Patients with Down syndrome exhibit reduced susceptibility to the majority of solid tumors, although biliary malignancies have been hypothesized to represent a possible yet unconfirmed epidemiological exception. Congenital pancreatobiliary malformations, early-onset cholelithiasis, and chronic inflammation have been postulated as plausible contributing factors for biliary malignancies; nevertheless, comprehensive case reports of biliary tract cancer in patients with Down syndrome remain scarce. Herein, we describe a female patient with Down syndrome who was diagnosed with perihilar cholangiocarcinoma (pCCA) by EUS-FNA, and summarize her diagnostic journey and clinical treatment course. A 52-year-old female with Down syndrome presented with a 3-week history of progressive obstructive jaundice. Imaging confirmed Bismuth type IIIa perihilar cholangiocarcinoma (pCCA), which was initially assessed as technically resectable. Selective left-hepatic-duct percutaneous transhepatic cholangial drainage (PTCD) was performed for preoperative biliary decompression. After discussion of the anticipated risks and benefits, the patient’s family declined radical surgical resection. Transgastric endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was subsequently performed, and pathological examination confirmed biliary adenocarcinoma. Genomic profiling identified concurrent somatic ERBB2 p.S310F activating mutation and ERBB2 gene amplification. The tumour was microsatellite-stable, with a tumour mutational burden of 10.52 mutations/Mb. Following multidisciplinary team (MDT) evaluation, the current first-line standard—gemcitabine plus cisplatin combined with an immune checkpoint inhibitor—was deemed not feasible because of the patient's malnutrition, hypoalbuminaemia, unintentional weight loss and frailty. She was therefore treated with trastuzumab in combination with oral S-1. After six months of treatment, stable disease was documented according to the Response Evaluation Criteria in Solid Tumours (RECIST), version 1.1. The treatment was generally well tolerated, with only CTCAE grade 2 vomiting observed. In this patient, transgastric EUS-FNA enabled histological diagnosis and molecular profiling, and trastuzumab combined with S-1 was administered for 6 months without grade ≥ 3 treatment-related adverse events. Further evidence is required before the diagnostic or therapeutic approach can be generalized.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: